ANZCTR search results

Each participant will receive physiotherapy treatment involving one-on-one education about physical activity for heart failure, including guidelines for walking and exercise while an inpatient at The Prince Charles Hospital. A walking and exercise program for home will also be provided before discharge. In addition, those in the walking group will receive twice daily walking supervised by a physiotherapist. Treatment will take up to 40 minutes each day to complete and will be carried out each day until discharge. All participants will undergo an assessment prior to discharge involving a walking test to measure walking capacity in 6 minutes and activity levels. Soon after discharge activity levels will again be monitored and all participants will receive surveys looking at quality of life and return to everyday activity in the community.

In treatment naïve HIV infected subjects, combination antiretroviral therapy including efavirenz combined with tenofovir and emtricitabine will offer non-inferior antiretroviral efficacy over 48 weeks, compared to either atazanavir boosted with ritonavir combined with tenofovir and emtricitabine or tenofovir and emtricitabine combined with zidovudine and abacavir, as assessed by change from baseline plasma HIV-1 RNA viral load.

The recommended dosage for some drugs currently used to treat HIV infection is highly effective but clinical data suggests that the doses could be reduced without compromising their effectiveness. Lower drug doses could have fewer side effects and could be tolerated better, making it easier for people to take and stay on their anti-HIV medication. Dose reduction would also make the drugs cheaper; this would allow more people to be treated and free up money for other important work in the fight against HIV such as education and prevention programs. Two different regimens containing either the standard dose or a reduced dose of efavirenz will be compared: I. efavirenz 600mg + truvada (tenofovir and emtricitabine) II. efavirenz 400mg + truvada (tenofovir and emtricitabine) Tenofovir, emtricitabine and efavirenz are all licensed as individual drugs for the treatment of HIV disease in many countries around the world. Efavirenz is only licensed at the standard dose of 600mg. Emtricitabine and tenofovir are provided as a fixed dose combination that is not currently licensed in every country involved in this study. A fixed dose combination means that the two drugs are incorporated into one pill.

This study will assess the safety of THVD-201 and how well it is tolerated. It will investigate the effects on your bladder symptoms of THVD-201 compared to tolterodine alone, and placebo. The study will also investigate whether the combination treatment reduces the unwanted side effects associated with taking tolterodine alone.

This study formally investigates specific breathing exercises, using a threshold device, for patients who require a breathing machine. It is hoped that the study will demonstrate that this training reduces breathing muscle weakness and also enhances quality of life, with significant improvements even 2 weeks following weaning from the breathing machine. The results of this study will guide physiotherapists in the optimal treatment of breathing muscle weakness for patients who have needed a breathing machine.

Previous studies of “diastolic heart failure” have been limited by confusion about the definition of this entity, and evidence for specific treatments are undefined. The characterization of IFPE will permit us to identify a homogeneous group. However, the most appropriate therapeutic response to increased filling pressure causing exertional dyspnea is undefined.

This study will examine whether a correlation exists between contamination of contact lens cases with Stenotrophomonas maltophilia and CIEs, when contact lenses and worn on a daily wear basis. The hypothesis is case contamination with Stenotrophomonas maltophilia does not correlate with CIEs.

It has been established that regular aerobic activity enhances synaptic plasticity, but it is not known whether a single session of exercise promotes neuroplasticity within the motor cortex of the brain. The mechanisms which might mediate this effect are likely to involve changes in expression or concentrations of key neurotrophins such as brain-derived neurotrophic factor. Our specific hypothesis is that a single session of aerobic exercise will enhance neuroplasticity in the brain.

Based on previous studies reported in the literature (Riley et al., 2007; Steele & Wade, 2008) we propose that a treatment that targets clinical perfectionism will be as effective as a treatment that targets anxiety and depression. Due to only a small number of trials to date, with relatively small sample sizes, our study is required to effectively test this hypothesis in a Randomised Control Trial with an adequate sample size.

In this 2-part study, a total of 48 healthy male subjects will be enrolled and will be randomized to 1 of 8 sequences (4 in each study part), in groups of 4 subjects each. Part A of the study will be a 3-way crossover design. Part A1 will evaluate two single ascending doses of the single agent C-10276 (an ATV isotopolog), and a dose of Reyataz. Part A2 will evaluate the single agent C-10276 at two dose levels and co-administration of CTP-518 and C-10276. Part B will consist of two subparts. In the first subpart, C-10297 and C-10299 will be administered in 200 mg doses, in two groups of 4 subjects each. The second subpart consists of three groups of 8 subjects that will participate in a 3-way partial crossover study design. C-10297 and C-10299 will be administered in 400 and 600 mg doses, C-10276 will be administered in 600 mg and Reyataz will be dosed in 400 and 600 mg doses. All study drug doses, including the comparator, Reyataz, will be administered as single, open-labeled doses to subjects after a light meal. There will be a 7-day washout between individual subjects’ doses.